New Signaling Pathways Associated With Increased Cardiac Adenylyl Cyclase 6 Expression: Implications for Possible Congestive Heart Failure Therapy

Trends in Cardiovascular Medicine

Volumn 17, Issue 7, 2007, Pages 215-221

  Phan, Huy M ^a,b   Gao, Mei Hua ^a,b   Lai, N Chin ^a,b   Tang, Tong ^a,b   Hammond, H Kirk ^a,b  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ADENYLATE CYCLASE; ADENYLYL CYCLASE 6; BETA ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; MESSENGER RNA; TACROLIMUS; UNCLASSIFIED DRUG;

ADENOVIRUS; ATRIOVENTRICULAR BLOCK; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; ECONOMIC ASPECT; ENZYME ACTIVITY; GENE THERAPY; GENE TRANSFER; HEART FUNCTION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; MORBIDITY; MORTALITY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVIEW; SIGNAL TRANSDUCTION; SURVIVAL; TRANSGENE;

ADENYLATE CYCLASE; CALCIUM; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEART; HEART FAILURE; HUMANS; PREVALENCE; PROGNOSIS; RECEPTORS, ADRENERGIC, BETA; SIGNAL TRANSDUCTION;

EID: 34948894945     PISSN: 10501738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tcm.2007.07.001     Document Type: Review

References (67)

1. Antos C.L., Frey N., Marx S.O., et al. Dilated cardiomyopathy and sudden death resulting from constitutive activation of protein kinase A. Circ Res 89 (2001) 997-1004
2. Beazely M.A., Alan J.K., and Watts V.J. Protein kinase C and epidermal growth factor stimulation of Raf1 potentiates adenylyl cyclase type 6 activation in intact cells. Mol Pharmacol 67 (2005) 250-259
3. Beazely M.A., and Watts V.J. Regulatory properties of adenylate cyclases type 5 and 6: a progress report. Eur J Pharmacol 535 (2006) 1-12
4. Bers D.M. Altered cardiac myocyte Ca regulation in heart failure. Physiology (Bethesda) 21 (2006) 380-387
5. Bristow M.R., Ginsburg R., Minobe W., et al. Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. N Engl J Med 307 (1982) 205-211
6. Brodde O.E., Bruck H., and Leineweber K. Cardiac adrenoceptors: physiological and pathophysiological relevance. J Pharmacol Sci 100 (2006) 323-337
7. D'Angelo D.D., Sakata Y., Lorenz J.N., et al. Transgenic Gαq overexpression induces cardiac contractile failure in mice. Proc Natl Acad Sci U S A 94 (1997) 8121-8126
8. Engelhardt S., Hein L., Wiesmann F., and Lohse M.J. Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A 96 (1999) 7059-7064
9. Feldman A.M. Adenylyl cyclase: a new target for heart failure therapeutics. Circulation 105 (2002) 1876-1878
10. Feldman M.D., Copelas L., Gwathmey J.K., et al. Deficient production of cyclic AMP: pharmacological evidence of an important cause of contractile dysfunction in patients with end-stage heart failure. Circulation 75 (1987) 331-339
11. Fishman G.I. Conditional transgenics. Trends Cardiovasc Med 5 (1995) 211-217
12. Fishman G.I. Timing is everything in life: conditional transgene expression in the cardiovascular system. Circ Res 82 (1998) 837-844
13. Gao M.H., Ping P., Post S., et al. Increased expression of adenylylcyclase type VI proportionately increases beta-adrenergic receptor-stimulated production of cAMP in neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 95 (1998) 1038-1043
14. Gao M.H., Lai N.C., Roth D.M., et al. Adenylylcyclase increases responsiveness to catecholamine stimulation in transgenic mice. Circulation 99 (1999) 1618-1622
15. Gao M.H., Bayat H., Roth D.M., et al. Controlled expression of cardiac-directed adenylylcyclase type VI provides increased contractile function. Cardiovasc Res 56 (2002) 197-204
16. Gao M.H., Tang T., Guo T., et al. Adenylyl cyclase type VI gene transfer reduces phospholamban expression in cardiac myocytes via activating transcription factor 3. J Biol Chem 37 (2004) 38797-38802
17. Gao M.H., Tang T., Guo T., et al. Adenylyl cyclase type VI regulates Akt activity through a PH domain leucine-rich repeat protein phosphatase. Mol Ther 15 (2007) 454 [Abstract]
18. Gao X., Sadana R., Dessauer C.W., et al. Conditional stimulation of type V and VI adenylyl cyclases by G protein beta gamma subunits. J Biol Chem 282 (2007) 294-302
19. Grines C.L., Watkins M.W., Helmer G., et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 105 (2002) 1291-1297
20. Hajjar R.J., Schmidt U., Matsui T., et al. Modulation of ventricular function through gene transfer in vivo. Proc Natl Acad Sci U S A 95 (1998) 5251-5256
21. Hanoune J., and Defer N. Regulation and role of adenylyl cyclase isoforms. Annu Rev Pharmacol Toxicol 41 (2001) 145-174
22. Head B.P., Patel H.H., Roth D.M., et al. Microtubules and actin microfilaments regulate lipid raft/caveolae localization of adenylyl cyclase signaling components. J Biol Chem 281 (2006) 26391-26399
23. Hoshijima M., Knoll R., Pashmforoush M., and Chien K.R. Reversal of calcium cycling defects in advanced heart failure toward molecular therapy. J Am Coll Cardiol 48 9 Suppl 1 (2006) A15-A23
24. Ishikawa Y., and Homcy C.J. The adenylyl cyclases as integrators of transmembrane signal transduction. Circ Res 80 (1997) 297-304
25. Ishikawa Y., Sorota S., Kiuchi K., et al. Downregulation of adenylylcyclase types V and VI mRNA levels in pacing-induced CHF in dogs. J Clin Invest 93 (1994) 2224-2229
26. Iwami G., Kawabe J., Ebina T., et al. Regulation of adenylyl cyclase by protein kinase A. J Biol Chem 270 (1995) 12481-12484
27. Iwanaga Y., Hoshijima M., Gu Y., et al. Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J Clin Invest 113 (2004) 727-736
28. Iwase M., Uechi M., Vatner D.E., et al. Cardiomyopathy induced by cardiac Gsα overexpression. Am J Physiol Heart Circ Physiol 272 (1997) 585-589
29. Kaspar B.K., Roth D.M., Lai N.C., et al. Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J Gene Med 7 (2005) 316-324
30. Kikura M., Morita K., and Sato S. Pharmacokinetics and a simulation model of colforsin daropate, new forskolin derivative inotropic vasodilator, in patients undergoing coronary artery bypass grafting. Pharmacology Res 49 (2004) 275-281
31. Lai N.C., Roth D.M., Gao M.H., et al. Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity. Circulation 102 (2000) 2396-2401
32. Lai N.C., Roth D.M., Gao M.H., et al. Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure. Circulation 110 (2004) 330-336
33. Lai N.C., Saito M., and Tang T. Activation of cardiac adenylyl cyclase type VI expression in the presence of severe heart failure increases LV systolic and diastolic function. Circulation 112 Suppl (2005) II-64 [Abstract]
34. Lehnart S.E., Terrenoire C., Reiken S., et al. Stabilization of cardiac ryanodine receptor prevents intracellular calcium leak and arrhythmias. Proc Natl Acad Sci U S A 103 (2006) 7906-7910
35. Liggett S.B., Tepe N.M., Lorenz J.N., et al. Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation 101 (2000) 1707-1714
36. Logeart D., Hatem S.N., Rucker-Martin C., et al. Highly efficient adenovirus-mediated gene transfer to cardiac myocytes after single-pass coronary delivery. Hum Gene Ther 11 (2000) 1015-1022
37. Marx S.O., Reiken S., Hisamatsu Y., et al. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. Cell 101 (2000) 365-376
38. Morgan J.P., Erny R.E., Allen P.D., et al. Abnormal intracellular calcium handling, a major cause of systolic and diastolic dysfunction in ventricular myocardium from patients with heart failure. Circulation 81 (1990) III21-III32
39. Most P., Remppis A., and Katus H.A. Conditional AC type VI expression in the heart: relevant insights into function of inducible target gene expression. Cardiovasc Res 56 (2002) 181-183
40. Nattel S., Maguy A., Le Bouter S., and Yeh Y.H. Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87 (2007) 425-456
41. Nayak L., and Rosengart T.K. Gene therapy for heart failure. Semin Thorac Cardiovasc Surg 17 (2005) 343-347
42. Oda T., Yano M., Yamamoto T., et al. Defective regulation of interdomain interactions within ryanodine receptor plays a key role in the pathogenesis of heart failure. Circulation 111 (2005) 3400-3410
43. Okumura S., Takagi G., Kawabe J., et al. Disruption of type 5 adenylyl cyclase gene preserves cardiac function against pressure overload. Proc Natl Acad Sci U S A 100 (2003) 9986-9990
44. Ping P., Anzai T., Gao M., and Hammond H.K. Adenylyl cyclase and G protein receptor kinase expression during development of heart failure. Am J Physiol Heart Circ Physiol 273 (1997) 707-717
45. Pleger S.T., Most P., Boucher M., et al. Stable myocardial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115 (2007) 2506-2515
46. Rabinowitz J.E., and Samulski J. Adeno-associated virus expression systems for gene transfer. Curr Opin Biotechnol 9 (1998) 470-475
47. Rebolledo B., Lai N.C., Gao M.H., et al. Adenylylcyclase gene transfer increases function of the failing heart. Hum Gene Ther 17 (2006) 1043-1048
48. Roth D.M., Gao M.H., Lai N.C., et al. Cardiac-directed adenylyl cyclase expression improves heart function in murine cardiomyopathy. Circulation 99 (1999) 3099-3102
49. Roth D.M., Bayat H., Drumm J.D., et al. Adenylyl cyclase increases survival in cardiomyopathy. Circulation 105 (2002) 1989-1994
50. Roth D.M., Lai N.C., Gao M.H., et al. Nitroprusside increases gene transfer associated with intracoronary delivery of adenovirus. Hum Gene Ther 15 (2004) 989-994
51. Sasano T., Kikuchi K., McDonald A.D., et al. Targeted high-efficiency, homogeneous myocardial gene transfer. J Mol Cell Cardiol 42 (2007) 954-961
52. Sastry A., Arnold E., Gurji H., et al. Cardiac-directed expression of adenylyl cyclase VI facilitates atrioventricular nodal conduction. J Am Coll Cardiol 48 (2006) 559-565
53. Sesti C., and Kloner R.A. Gene therapy in congestive heart failure. Circulation 110 (2004) 242-243
54. Sunahara R.K., Dessauer C.W., and Gilman A.G. Complexity and diversity of mammalian adenylyl cyclases. Annu Rev Pharmacol Toxicol 36 (1996) 461-480
55. Sunahara R.K., and Taussig R. Isoforms of mammalian adenylyl cyclase: multiplicities of signaling. Mol Interv 2 (2002) 168-184
56. Suzuki G., Lee T.C., Fallavollita J.A., and Canty J.M. Adenoviral gene transfer of FGF-5 to hibernating myocardium improves function and stimulates myocytes to hypertrophy and reenter the cell cycle. Circ Res 96 (2005) 767-775
57. Swaney J.S., Roth D.M., Olson E.R., et al. Inhibition of cardiac myofibroblast formation and collagen synthesis by activation and overexpression of adenylyl cyclase. Proc Natl Acad Sci U S A 102 (2005) 437-442
58. Takahashi T., Tang T., Lai N.C., et al. Increased cardiac adenylyl cyclase expression is associated with increased survival after myocardial infarction. Circulation 114 (2006) 388-396
59. Tang T., Gao M.H., Roth D.M., et al. Adenylyl cyclase type VI corrects cardiac sarcoplasmic reticulum calcium uptake defects in cardiomyopathy. Am J Physiol Heart Circ Physiol 287 (2004) 906-912
60. Tang T., Lai N.C., Roth D.M., et al. Adenylyl cyclase type V deletion increases basal left ventricular function and reduces left ventricular contractile responsiveness to β-adrenergic stimulation. Basic Res Cardiol 101 (2006) 117-126
61. Tepe N.M., and Liggett S.B. Transgenic replacement of type V adenylyl cyclase identifies a critical mechanism of beta-adrenergic receptor dysfunction in the Gαq overexpressing mouse. FEBS Lett 458 (1999) 236-240
62. Timerman A.P., Onoue H., Xin H.B., et al. Selective binding of FKBP12.6 by the cardiac ryanodine receptor. J Biol Chem 271 (1996) 20385-20391
63. Timofeyev V., He Y., Tuteja D., et al. Cardiac-directed expression of adenylyl cyclase reverses electrical remodeling in cardiomyopathy. J Mol Cell Cardiol 41 (2006) 170-181
64. Tobise K., Ishikawa Y., Holmer S.R., et al. Changes in type VI adenylyl cyclase isoform expression correlate with a decreased capacity for cAMP generation in the aging ventricle. Circ Res 74 (1994) 596-603
65. Tomaselli G.F., and Marban E. Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42 (1999) 270-283
66. 2+ handling in heart failure. J Clin Invest 115 (2005) 556-564
67. Wang T., and Brown M.J. Differential expression of adenylyl cyclase subtypes in human cardiovascular system. Mol Cell Endocrinol 223 (2004) 55-62